These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

639 related items for PubMed ID: 26130119

  • 21. Spironolactone for heart failure with preserved ejection fraction.
    Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, TOPCAT Investigators.
    N Engl J Med; 2014 Apr 10; 370(15):1383-92. PubMed ID: 24716680
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Longitudinal Strain in Heart Failure With Preserved Ejection Fraction: Is There a Role for Prognostication?
    Mentz RJ, Khouri MG.
    Circulation; 2015 Aug 04; 132(5):368-70. PubMed ID: 26130120
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
    Beldhuis IE, Myhre PL, Claggett B, Damman K, Fang JC, Lewis EF, O'Meara E, Pitt B, Shah SJ, Voors AA, Pfeffer MA, Solomon SD, Desai AS.
    JACC Heart Fail; 2019 Jan 04; 7(1):25-32. PubMed ID: 30606484
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, Rizkala A, Lukashevich I, O'Meara E, Ryan JJ, Shah SJ, Mullens W, Zile MR, Lam CSP, McMurray JJV, Solomon SD, PARAGON-HF Investigators.
    J Am Coll Cardiol; 2019 Dec 10; 74(23):2858-2873. PubMed ID: 31806129
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction.
    Shin SH, Claggett B, Inciardi RM, Santos ABS, Shah SJ, Zile MR, Pfeffer MA, Shah AM, Solomon SD.
    J Am Heart Assoc; 2021 Aug 03; 10(15):e019545. PubMed ID: 34325519
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: The PARAGON-HF study.
    Minamisawa M, Inciardi RM, Claggett B, Cikes M, Liu L, Prasad N, Biering-Sørensen T, Lam CSP, Shah SJ, Zile MR, O'Meara E, Redfield MM, McMurray JJV, Solomon SD, Shah AM.
    Eur J Heart Fail; 2024 Apr 03; 26(4):871-881. PubMed ID: 38369856
    [Abstract] [Full Text] [Related]

  • 35. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.
    Myhre PL, Vaduganathan M, Claggett BL, Anand IS, Sweitzer NK, Fang JC, O'Meara E, Shah SJ, Desai AS, Lewis EF, Rouleau J, Pitt B, Pfeffer MA, Solomon SD.
    JAMA Cardiol; 2018 Oct 01; 3(10):1000-1005. PubMed ID: 30140899
    [Abstract] [Full Text] [Related]

  • 36. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
    Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O'Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA, TOPCAT Investigators.
    Eur Heart J; 2016 Feb 01; 37(5):455-62. PubMed ID: 26374849
    [Abstract] [Full Text] [Related]

  • 37. Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.
    Rossignol P, Claggett BL, Liu J, Vardeny O, Pitt B, Zannad F, Solomon S.
    Am J Hypertens; 2018 Mar 10; 31(4):407-414. PubMed ID: 29228101
    [Abstract] [Full Text] [Related]

  • 38. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.
    Shah SJ, Heitner JF, Sweitzer NK, Anand IS, Kim HY, Harty B, Boineau R, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Lewis EF, Markov V, O'Meara E, Kobulia B, Shaburishvili T, Solomon SD, Pitt B, Pfeffer MA, Li R.
    Circ Heart Fail; 2013 Mar 10; 6(2):184-92. PubMed ID: 23258572
    [Abstract] [Full Text] [Related]

  • 39. Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT.
    Sperry BW, Hanna M, Shah SJ, Jaber WA, Spertus JA.
    JACC Heart Fail; 2021 Nov 10; 9(11):795-802. PubMed ID: 34509404
    [Abstract] [Full Text] [Related]

  • 40. Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial.
    Neefs J, van den Berg NWE, Krul SPJ, Boekholdt SM, de Groot JR.
    Am J Cardiovasc Drugs; 2020 Feb 10; 20(1):73-80. PubMed ID: 31214914
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.